Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 1999

View Archived Issues

Pravastatin activates eNOS, provides additional clinical benefits

Variagenics granted exclusive license for genetic marker of cardiovascular disease

Licensing opportunity from Yeda: iron chelators for treatment of neurologic disorders

Ligand and Ferrer enter marketing agreement for five Ligand products

ProScript receives SBIR grant for novel stroke treatment

AutoImmune and Lilly to restructure collaborative agreement for diabetes treatment

Schering-Plough seeks further E.U. approval for Temodal

FDA approves ANDA for Oruvail

New carbapenems synthesized at Merck useful against resistant staphylococci

Meiji Milk presents new therapeutics for dementia that stimulate neurite growth

Sanofi's new CRF antagonists: preparation, use and pharmaceutical compositions

PhotoVision in-licenses novel technology for development of AMD treatment

Growth factor receptor PTK inhibitors in development by American Cyanamid

Pfizer discloses new series of bradykinin antagonists

Glycine-site NMDA antagonist is safe and well tolerated in stroke patients

Selective NMDA antagonists in the Lilly pipeline

Novartis identifies thrombin inhibitors with improved pharmacodynamic and pharmacokinetic properties

Abgenix and BASF to collaborate on antibody development

Organon designs and synthesizes orally active thrombin inhibitors based on NAPAP

Novel antibiotic active against acid-fast bacteria presented at recent Japanese congress

LBP199-IgG1 Fc: a new endotoxin-neutralizing fusion protein

Identification and neuroprotective activity of GV-224029 discussed at ACS meeting

Roche, deCode Genetics close in on osteoarthritis disease-causing gene

Small-molecule N-type Ca2+ channel blockers designed by Neurex/Parke-Davis group

A new fluoroquinolone derivative effective against HIV-1

Merger of Astra and Zeneca now officially completed

Phytopharm assumes increased responsibility for development of unique botanical product

New orally active NEP inhibitor exerts beneficial effects in rabbit model of CHF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...